[Long-term effects of plasma exchange in myasthenia. Results of a randomized study]
- PMID: 6221247
[Long-term effects of plasma exchange in myasthenia. Results of a randomized study]
Abstract
A randomized study was carried out in 14 myasthenia patients to compare the long-term effects of two therapeutic regimens. Group I patients received prednisone 1 mg/kg/24 h for one month, then in decreasing dosage; in case of failure at the end of the first month, cyclophosphamide 2 mg/kg/24 h was added to the prednisone treatment. Group II patients received the same treatment associated with 3 plasma exchanges over a 10-day period; these were continued, if required, at the rate of once a week. The minimum follow up was one year. The results (greater improvement in muscular strength and vital capacity) were better after one month in group I and thereafter similar in both groups. However, the mean daily dose of prednisone was higher in Group I. The number of exacerbations of myasthenia was greater in group II (11 versus 2 in group I over a 24-months period). The mean fall in anti-R Ach ab was about the same in both groups. This study confirms the rapid effectiveness of plasma exchanges and their value in severe myasthenia. The higher incidence of exacerbations in Group II was probably due to a rebound phenomenon and points to the need for combined immuno-suppressive treatment.
Similar articles
-
[Favorable results of plasmapheresis in severe myasthenia gravis].Ned Tijdschr Geneeskd. 1997 Feb 22;141(8):381-4. Ned Tijdschr Geneeskd. 1997. PMID: 9157298 Dutch.
-
Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.Ann Neurol. 1997 Jun;41(6):789-96. doi: 10.1002/ana.410410615. Ann Neurol. 1997. PMID: 9189040 Clinical Trial.
-
The treatment of severe forms of myasthenia gravis.Funct Neurol. 1998 Jul-Sep;13(3):231-7. Funct Neurol. 1998. PMID: 9800150 Clinical Trial.
-
Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis.J Clin Neurosci. 2014 Nov;21(11):1909-14. doi: 10.1016/j.jocn.2014.03.019. Epub 2014 Jul 17. J Clin Neurosci. 2014. PMID: 25043165
-
[Contribution of intravenous immunoglobulins to the treatment of myasthenia].Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S30-4. Ann Med Interne (Paris). 2000. PMID: 10896986 Review. French.
Cited by
-
Weaning from mechanical ventilation during myasthenic crisis, a monocentric retrospective study.Sci Rep. 2024 Aug 22;14(1):19523. doi: 10.1038/s41598-024-70373-y. Sci Rep. 2024. PMID: 39174610 Free PMC article.
-
Understanding the burden of refractory myasthenia gravis.Ther Adv Neurol Disord. 2019 Mar 1;12:1756286419832242. doi: 10.1177/1756286419832242. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 30854027 Free PMC article. Review.
-
Current and emerging treatments for the management of myasthenia gravis.Ther Clin Risk Manag. 2011;7:313-23. doi: 10.2147/TCRM.S14015. Epub 2011 Jul 22. Ther Clin Risk Manag. 2011. PMID: 21845054 Free PMC article.
-
Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence.Front Neurol. 2021 Aug 31;12:662856. doi: 10.3389/fneur.2021.662856. eCollection 2021. Front Neurol. 2021. PMID: 34531809 Free PMC article.
-
Plasma exchange for myasthenia gravis.Cochrane Database Syst Rev. 2002;2002(4):CD002275. doi: 10.1002/14651858.CD002275. Cochrane Database Syst Rev. 2002. PMID: 12519572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical